吉西他滨联合顺铂与紫杉醇联合顺铂治疗晚期非小细胞肺癌的临床研究  

Clinical study of TP and GP in treating advanced non- small cell lung cancer

作　　者：王心玲[1] 李红[1] 王大本[1] 张玉梅[1] 

机构地区：[1]济南市第五人民医院肿瘤科,250022

出　　处：《国际肿瘤学杂志》2009年第10期795-797,共3页Journal of International Oncology

摘　　要：目的探讨吉西他滨联合顺铂（GP）方案和紫杉醇联合顺铂（TP）方案对初治的晚期非小细胞肺癌（NSCLC）的疗效和不良反应。方法66例初治晚期NSCLC患者随机分为GP组（34例）和TP组（32例）。GP组：吉西他滨1000mg／m^2，第1、8天；顺铂30mg／m^2，第1—3天。11）组：紫杉醇135mg／m^2，第1天；顺铂30mg／m^2，第1～3天。化疗2个周期后对两组的临床疗效和不良反应进行评价。结果GP和TP两组的有效率分别为41．2％（14／34）和40．6％（13／32）。两组资料比较差异无统计学意义。GP组以血小板降低为主，TP组以白细胞降低为主，均在可耐受范围内。结论GP方案和TP方案对晚期NSCLC疗效肯定，不良反应有一定差异，可根据不同个体选用不同的化疗方案。Objective To investigate the efficacy and toxicity of the GP regimen and TP regimen on advanced non-small cell lung cancer（NSCLC）. Methods Sixty-six advanced NSCLC patients were randomly divided into two groups. 34 in GP group and 32 in TP group. GP group ：gemeitabine 1000 mg/m^2, dl ,d8 ;eisplatin 30 mg/m^2 ,d1 -3. TP group： paelitaxel 135 mg/m^2, dl ; eisplatin 30 mg/m^2, d1 -3. The efficacy and side effects were analyzed after two cycles of chemotherapy. Results The short term effective rate for advanced NSCLC in GP group and TP group was 41.2% （14/34） and 40. 6% （13/32） ,no significant statistical difference was found between the two groups （ P 〉 0. 05 ）. In the adverse effects of treatment, the major eytotoxieity was thromboeytopenia in GP group and leukopenia in TP group but they were tolerable. Conclusion The curative effect of GP regimen and TP regimen are affirmed, there are certain differences in adverse reactions. Different themes can be chosen according to different choices in patients with advanced non-small cell lung cancer.

关 键 词：癌 非小细胞肺 吉西他滨 紫杉醇 顺铂 药物疗法 联合 

分 类 号：R734.2[医药卫生—肿瘤] R979.1[医药卫生—临床医学]